The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...
Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...
Overall, mortality was lower, and lesions resolved faster than anticipated – regardless of whether participants received tecovirimat or placebo, according to the NIH. Tecovirimat was found to be ...
Tecovirimat 200mg/vial; soln for IV infusion after dilution; contains hydroxypropyl-β-cyclodextrin. Store Tpoxx injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback